Breaking News

Celltrion Launches Bio CDMO Business

Initial focus will be placed on autoimmune diseases, breast cancer, blood cancer and cardiovascular diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Celltrion recently launched its Bio CDMO business in a bid to pursue open innovation for the development of new drugs. The company said its Bio CDMO operations will focus on the outsourcing of biologic cell line development and production process, and the manufacture and outsourcing of non-clinical material, clinical material, and commercialized material. Celltrion’s CDMO business aims to collaborate and partner with research institutes and biotech firms, possessing a new drug candid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters